News

In newly diagnosed hypertension with OSA, adding CPAP augmented the benefits of losartan

View on the News

Treating OSA a “worthy goal” for BP

Treating OSA may make hypertension easier to address pharmacologically. The effect of CPAP on blood pressure is relatively small when all patients are considered but is more substantial and clinically important for those who use CPAP for more than 4 hours per night.

Can treatment of OSA effectively reduce blood pressure in an otherwise asymptomatic hypertensive patient with OSA? I believe the study would suggest that the answer remains “maybe.”

Most of the patients in the study would require a higher dose of losartan or an additional antihypertensive drug, even while using CPAP, to get to target blood pressures. Getting patients to use CPAP is a difficult task, as is adherence with any long-term pharmacologic management.

All in all, however, CPAP could contribute to blood pressure control while also improving quality of life and possibly reducing the risk for cardiovascular disease.

Dr. David P. White is with Harvard Medical School in Boston. His comments are excerpted from an accompanying editorial (Am J Respir Crit Care Med. 2016 Feb;193:238-9).


 

FROM AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

References

In patients with new-onset hypertension and obstructive sleep apnea, continuous positive airway pressure (CPAP) therapy plus antihypertensive treatment with losartan led to reductions in systolic blood pressure beyond those achieved with losartan alone, a two-phase study found.

“Adding CPAP treatment to losartan may reduce blood pressure in a clinically relevant way if the patients are compliant with the device,” said Dr. Erik Thunström of the Sahlgrenska Academy at the University of Gothenburg, Sweden, and his associates.

©viola83181/iStockphoto.com

In their open-label study, 89 men and women with new-onset untreated hypertension – 54 of whom were found to have obstructive sleep apnea (OSA) through a home sleep study and 35 of whom were determined to not have OSA – were treated for 6 weeks with losartan, 50 mg daily. Ambulatory 24-hour blood pressure monitoring was performed before and after treatment.

The patients with OSA were then randomized to receive 6 weeks of nightly add-on CPAP therapy or to continue losartan alone. Ambulatory 24-hour blood pressure monitoring was performed again.

Losartan alone reduced blood pressure in patients with hypertension and concomitant OSA, but the effect was smaller than that seen in patients without OSA. Statistically significant differences were seen in the mean net reduction in morning systolic blood pressure and morning mean arterial pressure. Overall, losartan appeared to be less effective at night and during the early morning hours in patients with OSA, the researchers reported.

After 6 weeks of losartan alone, a blood pressure less than 130/80 mm Hg was achieved by 12.5% of the patients with OSA and by 29% of the patients without OSA.

After 6 weeks of add-on CPAP therapy, 25% of patients with OSA achieved blood pressures less than 130/80 mm Hg. The differences in blood pressures for the OSA patients receiving CPAP plus losartan and those receiving losartan alone were 4.4 mm Hg for 24-hour systolic blood pressure, 1.9 mm Hg for diastolic, and 2.5 mm Hg for mean arterial pressure.

The most “robust” blood pressure changes were seen in the patients who used CPAP therapy for more than 4 hours every night, reducing the mean 24-hour systolic blood pressure by 6.5 mm Hg, the diastolic pressure by 3.8 mm Hg, and the mean arterial blood pressure by 4.6 mm Hg, the researchers reported (Am J Respir Crit Care Med. 2016 Feb.;193:310-20). “Adding CPAP to treatment with losartan reduced the mean 24-hour systolic blood pressure by 6.5 mm Hg in the subgroup of patients with OSA who were adherent with CPAP,” they wrote.

Patients included in the study all had a body mass index of 35 kg/m2; those with OSA had slightly higher BMIs that did not differ significantly from those without OSA.

That CPAP seems to have additive blood pressure–lowering effect when used concomitantly with losartan “favors the idea that it contributes to a further down-regulation of RAAS [renin-angiotensin-aldosterone system] activity in new-onset hypertension and OSA,” the authors wrote.

RAAS activity is often changed in hypertension, and in animal studies it has been shown to be up-regulated by intermittent hypoxia. Angiotensin II receptor antagonists are thus viewed as a good choice in the treatment of patients with OSA and new-onset hypertension, they wrote.

Recommended Reading

New ROCKET-AF review claims faulty INR monitoring device didn’t affect results
MDedge Neurology
What’s next for Watchman stroke prevention device
MDedge Neurology
COPD exacerbation amps up stroke risk
MDedge Neurology
Influenza linked to atrial fibrillation in large observational study
MDedge Neurology
Elevated cardiovascular risks linked to hidradenitis suppurativa
MDedge Neurology
VIDEO: Migraine plus aura doubles ischemic stroke rate
MDedge Neurology
VIDEO: Post-stroke pioglitazone modestly protective against secondary vascular events
MDedge Neurology
VIDEO: Octogenarians benefit from ischemic stroke thrombectomy
MDedge Neurology
ISC: Carotid surgery, stenting offer patients balanced alternatives
MDedge Neurology
ISC: Pick up extra AF with extended Holter monitoring
MDedge Neurology